Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EYPT Stock 12 Month Forecast
Average Price Target
$25.86
▲(166.32%Upside)
| Highest Price Target$41.00 | Average Price Target$25.86 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$10.5
Hold
8.14%
Upside
Reiterated
07/29/25
EyePoint Pharmaceuticals' stock score is primarily influenced by its financial challenges, offset by strong clinical trial progress and technical momentum. The negative valuation due to poor earnings is a significant risk, but optimism from strategic developments and market potential for DURAVYU offers a positive outlook.
JonesTrading
$41
Buy
322.25%
Upside
Reiterated
08/01/25
Buy Rating for EyePoint Pharmaceuticals: Duravyu's Competitive Edge and Reliability Drive Investment ConfidenceWe emphasize a key difference that LUCIA has enrolled and randomized its 400+ patients. Topline 56-Wk data from Duravyu's Ph3 LUGANO trial is expected in mid-26, with LUCIA readout to follow closely.
H.C. Wainwright
$22
Buy
126.57%
Upside
Reiterated
07/30/25
Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market ValuationValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $1.48B, which includes a discounted cash flow (DCF) based asset value of $1.17B for DURAVYU (with 65% probability of approval), with a 15% discount rate and 2% terminal growth rate, and $318.2M cash.
RBC Capital
$28
Buy
188.36%
Upside
Reiterated
07/29/25
Mizuho Securities
$26
Buy
167.77%
Upside
Reiterated
07/29/25
Scotiabank
$18
Buy
85.38%
Upside
Reiterated
05/28/25
J.P. Morgan
$26
Buy
167.77%
Upside
Reiterated
05/27/25
TD Cowen
$20
Buy
105.97%
Upside
Reiterated
05/07/25
Guggenheim
$68
Buy
600.31%
Upside
Reiterated
03/06/25
Cantor Fitzgerald
―
Buy
―
Reiterated
02/05/25
Citi
$33
Buy
239.86%
Upside
Initiated
01/07/25
Robert W. Baird
$38→$33
Buy
239.86%
Upside
Reiterated
11/11/24
Capital One Financial
$35
Buy
260.45%
Upside
Assigned
10/28/24
Jefferies
$15
Buy
54.48%
Upside
Reiterated
08/28/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$10.5
Hold
8.14%
Upside
Reiterated
07/29/25
EyePoint Pharmaceuticals' stock score is primarily influenced by its financial challenges, offset by strong clinical trial progress and technical momentum. The negative valuation due to poor earnings is a significant risk, but optimism from strategic developments and market potential for DURAVYU offers a positive outlook.
JonesTrading
$41
Buy
322.25%
Upside
Reiterated
08/01/25
Buy Rating for EyePoint Pharmaceuticals: Duravyu's Competitive Edge and Reliability Drive Investment ConfidenceWe emphasize a key difference that LUCIA has enrolled and randomized its 400+ patients. Topline 56-Wk data from Duravyu's Ph3 LUGANO trial is expected in mid-26, with LUCIA readout to follow closely.
H.C. Wainwright
$22
Buy
126.57%
Upside
Reiterated
07/30/25
Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market ValuationValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $1.48B, which includes a discounted cash flow (DCF) based asset value of $1.17B for DURAVYU (with 65% probability of approval), with a 15% discount rate and 2% terminal growth rate, and $318.2M cash.
RBC Capital
$28
Buy
188.36%
Upside
Reiterated
07/29/25
Mizuho Securities
$26
Buy
167.77%
Upside
Reiterated
07/29/25
Scotiabank
$18
Buy
85.38%
Upside
Reiterated
05/28/25
J.P. Morgan
$26
Buy
167.77%
Upside
Reiterated
05/27/25
TD Cowen
$20
Buy
105.97%
Upside
Reiterated
05/07/25
Guggenheim
$68
Buy
600.31%
Upside
Reiterated
03/06/25
Cantor Fitzgerald
―
Buy
―
Reiterated
02/05/25
Citi
$33
Buy
239.86%
Upside
Initiated
01/07/25
Robert W. Baird
$38→$33
Buy
239.86%
Upside
Reiterated
11/11/24
Capital One Financial
$35
Buy
260.45%
Upside
Assigned
10/28/24
Jefferies
$15
Buy
54.48%
Upside
Reiterated
08/28/24
Best Analysts Covering EyePoint Pharmaceuticals
1 Month
xxx
Success Rate
7/14 ratings generated profit
Average Return
-4.29%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -4.29% per trade.
3 Months
xxx
Success Rate
7/13 ratings generated profit
Average Return
+32.02%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +32.02% per trade.
1 Year
Success Rate
6/9 ratings generated profit
Average Return
+14.62%
reiterated a buy rating 2 days ago
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +14.62% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
Average Return
+14.62%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +14.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EYPT Analyst Recommendation Trends
Rating
Mar 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
12
20
18
15
5
Buy
2
2
0
0
0
Hold
0
3
7
12
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
25
25
27
14
Each month's total comprises the sum of three months' worth of ratings.
EYPT Financial Forecast
EYPT Stock Forecast FAQ
What is EYPT’s average 12-month price target, according to analysts?
Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 25.86.
What is EYPT’s upside potential, based on the analysts’ average price target?
EyePoint Pharmaceuticals Inc has 166.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EYPT a Buy, Sell or Hold?
EyePoint Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is EyePoint Pharmaceuticals Inc’s price target?
The average price target for EyePoint Pharmaceuticals Inc is 25.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $41.00 ,the lowest forecast is $18.00. The average price target represents 166.32% Increase from the current price of $9.71.
The highest analyst price target is $41.00 ,the lowest forecast is $18.00. The average price target represents 166.32% Increase from the current price of $9.71.
What do analysts say about EyePoint Pharmaceuticals Inc?
EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of EYPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.